Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults Journal Article

Authors: Kolb, E. A.; Kushner, B. H.; Gorlick, R.; Laverdiere, C.; Healey, J. H.; LaQuaglia, M. P.; Huvos, A. G.; Qin, J.; Vu, H.; Wexler, L.; Wolden, S.; Meyers, P. A.
Article Title: Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults
Abstract: Purpose: To improve the long-term event-free survival of patients with Ewing's family of tumors (EFTs) using high-dose, short-term chemotherapy. Patients and Methods: P6 was a prospective study of previously untreated patients with newly diagnosed EFTs. Patients received seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 consisted of cyclophosphamide 2,100 mg/m2/d on days 1 and 2, and a 72-hour continuous infusion of doxorubicin 75 mg/m2 and vincristine 2 mg/m2 starting day 1. Cycles 4, 5, and 7 consisted of 5 consecutive days of ifosfamide 1,800 mg/m2/d and etoposide 100 mg/m2/d. Results: Sixty-eight patients were enrolled from 1991 to 2001 (median age, 18.7 years; range, 3.7 to 39.9 years). At diagnosis, 44 patients had local-regional disease, and 24 had distant metastases. The 4-year event-free survival (EFS) rate for patients with local-regional disease is 82%; overall survival (OS) is 89%. The 4-year EFS rate for patients with distant metastases is 12%; the OS rate is 17.8%. All events occurred within 51 months of diagnosis. Four patients with distant metastases had progressive disease during therapy, and no patient with local-regional disease experienced disease progression during therapy. Conclusion: Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with local-regional EFTs. This therapy is relatively ineffective in the treatment of metastatic EFTs. © 2003 by American Society of Clinical Oncology.
Keywords: adolescent; adult; cancer chemotherapy; cancer survival; child; controlled study; preschool child; bone neoplasms; child, preschool; disease-free survival; bone tumor; survival rate; major clinical study; clinical trial; disease course; mortality; doxorubicin; disease free survival; antineoplastic agent; prospective study; prospective studies; metastasis; controlled clinical trial; multiple cycle treatment; phase 2 clinical trial; etoposide; antineoplastic combined chemotherapy protocols; recurrence; combination chemotherapy; cyclophosphamide; vincristine; continuous infusion; pathology; ifosfamide; ewing sarcoma; intensive care; disease progression; remission; remission induction; recurrent disease; sarcoma, ewing's; humans; human; male; female; priority journal; article; ivad protocol
Journal Title: Journal of Clinical Oncology
Volume: 21
Issue: 18
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2003-09-15
Start Page: 3423
End Page: 3430
Language: English
DOI: 10.1200/jco.2003.10.033
PUBMED: 12972518
PROVIDER: scopus
Notes: Export Date: 12 September 2014 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Brian Kushner
    190 Kushner
  2. Suzanne L Wolden
    419 Wolden
  3. Richard G Gorlick
    120 Gorlick
  4. Leonard H Wexler
    130 Wexler
  5. Jing Qin
    86 Qin
  6. Paul Meyers
    244 Meyers
  7. John H Healey
    374 Healey
  8. Anders E Kolb
    16 Kolb
  9. Andrew G Huvos
    202 Huvos
  10. Ha   Vu
    1 Vu